BioMarin Pharmaceutical's investigational gene therapy for severe hemophilia A Roctavian, or valoctocogene roxaparvovec, was granted regenerative medicine advanced therapy designation by the FDA. The single infusion therapy is delivered directly into the bloodstream to carry the functional gene copy to the liver.
BioMarin's hemophilia A gene therapy gets RMAT tag
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.